• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Eleven new members join DF/HCC

Eleven individuals have recently joined DF/HCC. See below to learn more about these scientists and their research interests.

Aditya Bardia, MD, MPH (MGH)
Breast Cancer, Cancer Epidemiology
Research focus: The lab focuses on developing predictive biomarkers and algorithms to maximize efficacy and minimize harms of therapeutic agents and thus personalize therapies for breast cancer, including evaluating large databases to identify potential biomarkers, as well as conducting biomarker driven clinical trials to evaluate blood based biomarkers (such as circulating tumor cells) and tissue based biomarkers (such as gene signatures) to predict response (or lack thereof) of a particular chemotherapy or targeted therapy.

Andrew Beck, MD (BIDMC)
Biostatistics and Computational Biology, Breast Cancer
Research focus: The goal of the lab’s work is to develop, apply, and integrate methods in molecular pathology, bio-informatics, and epidemiology for translational cancer genomics research, with a major focus being the study of breast cancer at all stages of breast carcinogenesis.

Theodore Hong, MD (MGH)
Gastrointestinal Malignancies
Research focus: The lab focuses on clinical trials with advanced radiation and integration with targeted therapies, collaborative efforts to bring new agents to clinical trial, and biomarkers that predict outcomes to radiation or chemoradiation.

Sanjeeva Kalva, MD (MGH)
Cancer Imaging, Gastrointestinal Malignancies
Research focus: The lab is involved in research studies related to trans-arterial therapy of liver cancer through chemoembolization using drug-eluting microspheres and radiation-emitting-microspheres.

David Kozono, MD, PhD (DFCI)
Lung Cancer
Research focus: The goal is to improve treatment for patients with locally advanced non-small cell lung carcinoma (LA-NSCLC). Efforts are therefore focused on increasing the ability of RT to selectively kill cancer cells using radiosensitizing drugs, or to protect the surrounding normal tissues. Other efforts include characterization of tumor molecular subtypes that indicate higher doses of radiation for locoregional control, or patient factors that correlate with higher toxicities.

Joyce Liu, MD, MPH (DFCI)
Gynecologic Cancers
Research focus: The research area of focus is ovarian cancer, with a particular emphasis on the identification and validation of novel therapeutic ovarian cancer targets through in vitro and in vivo models.

Takahiro Maeda, MD, PhD (BWH)
Leukemia, Lymphoma and Myeloma
Research focus: The research goal is to elucidate the molecular mechanisms underlying normal and malignant hematopoiesis, while maintaining keenly translational focus, by utilizing biochemical and molecular biological approaches and employing genetically modified mouse models. Specifically, the current research focuses on molecules/pathways relevant to hematological malignancies, such as LRF transcription factor, Notch and endocytic adopter proteins.

Raymond Mak, MD (BWH)
Lung Cancer
Research focus: Research interests include developing clinically-applicable genetic predictors of radiation response for radiation therapy in lung cancer, with a focus on both tumor radiosensitivity based on tumor genotype (e.g. by KRAS and EGFR mutations in non-small cell lung cancer) and germline genetic analysis for prediction of increased risk of radiation-induced normal tissue toxicity. Combining these two approaches will allow for an integrated “personalized” radiation therapy approach with a goal of widening the therapeutic window.

Andrea Myers, MD, PhD (DFCI)
Gynecologic Cancers, Translational Pharmacology and Early Therapeutic Trials
Research focus: The research is focused on studying the PI3K pathway and its importance in the initiation, maintenance and treatment of endometrial cancer by utilizing cell line and mouse models of endometrial cancers to understand the biochemical mechanisms of the common PI3K pathway alterations in endometrial cancers.

Laurence Turka, MD (BIDMC)
Cancer Immunology
Research focus: By conditionally deleting PTEN in T lymphocytes, the lab hopes to study its role in lymphomagenesis and tolerance in mice, continuing a long-standing interest in T cell immunobiology, with a particular focus on peripheral T cell immune responses and transplantation tolerance. Relevant to this application, the lab was amongst the first to demonstrate the role of  the costimulatory pathway in transplant rejection.

Anyong Xie, PhD (BIDMC)
Breast Cancer
Research focus: The primary major focus of the research is to understand how cells make a choice between homologous recombination (HR) and non-homologous end joining (NHEJ), two major double strand breaks (DSB) repair pathways, in mammalian DNA DSB repair. Another focus area is to understand targeting NHEJ in breast cancer therapy.